SEC files amended S-1/A for 21Shares Injective ETF tied to Injective

SEC: The U.S. Securities and Exchange Commission is the primary federal agency responsible for regulating securities markets and approving investment products such as exchange-traded funds. It evaluates registration statements including Form S-1 filings to ensure compliance with disclosure and investor protection standards. In the current news, the SEC has processed an amended S-1/A submission advancing the 21Shares Injective ETF toward potential listing. 21Shares Injective ETF: 21Shares is a leading issuer of cryptocurrency exchange-traded products focused on bridging traditional finance with digital assets through regulated vehicles. The 21Shares Injective ETF is a proposed spot product designed to provide U.S. investors with exposure to the Injective token via a conventional ETF wrapper. The recent amended filing with the SEC represents a key step in its ongoing registration process alongside other pending INJ-related proposals. Market Access: Proposed INJ ETFs would offer traditional brokerage channels for exposure to the Injective ecosystem alongside existing regulated futures products. Regulatory Review: The SEC continues to advance multiple applications for spot cryptocurrency exchange-traded funds through formal filing amendments and reviews. Product Development: 21Shares has expanded its lineup of crypto exchange-traded products with several new filings targeting major digital assets in recent months.